MedTrace Logo

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

NCT05507606 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-08-19

No results posted yet for this study

Summary

This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

osimertinib 80mg/d

DRUG

Bevacizumab Biosimilar IBI305

Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years

DRUG

Carboplatin

Carboplatin AUC5, d1; was stopped after 4 cycles

DRUG

Pemetrexed

Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-08-01
Completion
2024-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507606 on ClinicalTrials.gov